John Cox

John Cox is a seasoned executive in the biotechnology industry, currently serving as the Chief Executive Officer of Dyne Therapeutics since March 2024. Cox also holds a position as a Member of the Board of Directors at Canopy Immuno-Therapeutics, which focuses on innovative treatments for autoimmune disorders. As Executive Chairman of Minovia Therapeutics since March 2019, Cox leads efforts in mitochondrial cell therapies for severe diseases. His previous roles include Chief Executive Officer at Repertoire Immune Medicines, where John drove the company’s mission to harness the immune system against various diseases, and Chief Executive Officer at Torque Therapeutics, focused on novel immuno-oncology therapies. Cox has extensive experience from his time at Bioverativ and Biogen, where John held numerous leadership positions, notably spearheading the successful spin-off of Bioverativ from Biogen. Academic qualifications include an MBA from the University of Michigan, an MSc in Cell Biology from California State University, and a Bachelor’s degree in Biology from Arizona State University.